Sequence information
Variant position: 579 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 1480 The length of the canonical sequence.
Location on the sequence:
ARAVYKDADLYLLDSPFGYL
D VLTEKEIFESCVCKLMANKT
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human ARAVYKDADLYLLDSPFGYLD VLTEKEIFESCVCKLMANKT
Gorilla ARAVYKDADLYLLDSPFGYLD VLTEKEIFESCVCKLMANKT
ARAVYKDADLYLLDSPFGYLD VLTEKEIFESCVCKLMANKT
Rhesus macaque ARAVYKDADLYLLDSPFGYLD VLTEKEIFESCVCKLMANKT
Chimpanzee ARAVYKDADLYLLDSPFGYLD VLTEKEIFESCVCKLMANKT
Mouse ARAVYKDADLYLLDSPFGYLD VFTEEQVFESCVCKLMANKT
Rat ARAVYKDADLYLLDSPFGYLD VLTEEQIFESCVCKLMASKT
Pig ARAVYKDADLYLLDSPFGYLD VLTEKEIFESCVCKLMANKT
Bovine ARAVYKDADLYLLDSPFGYLD VLTEKEIFESCICKLMANKT
Rabbit ARAVYKDADLYLLDSPFGYLD VLTEKEIFESCVCKLMANKT
Sheep ARAVYKDADLYLLDSPFGYLD VLTEKEIFESCVCKLMANKT
Horse ARAVYKDADLYLLDSPFGYLD VLTEKEIFESCVCKLMANKT
Xenopus laevis ARAVYKDADLYLLDSPFSYLD LFTEKEIFESCVCKLMANKT
Zebrafish ARAVYRDADLYLLDAPFTHLD IATEKEIFDKCLCKLMASKT
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 1480
Cystic fibrosis transmembrane conductance regulator
Topological domain
359 – 858
Cytoplasmic
Domain
423 – 646
ABC transporter 1
Literature citations
Search for mutations in pancreatic sufficient cystic fibrosis Italian patients: detection of 90% of molecular defects and identification of three novel mutations.
Brancolini V.; Cremonesi L.; Belloni E.; Pappalardo E.; Bordoni R.; Seia M.; Russo S.; Padoan R.; Giunta A.; Ferrari M.;
Hum. Genet. 96:312-318(1995)
Cited for: VARIANTS CF GLY-57; LYS-193 AND GLY-579;
Identification of a D579G homozygote cystic fibrosis patient with pancreatic sufficiency and minor lung involvement.
Picci L.; Cameran M.; Olante P.; Zacchello F.; Scarpa M.;
Hum. Mutat. 13:173-173(1999)
Cited for: VARIANT CF GLY-579;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.